{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:35Z","timestamp":1786985075239,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.bcp.2015.07.013","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T02:43:15Z","timestamp":1438396995000},"page":"147-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells"],"prefix":"10.1016","volume":"97","author":[{"given":"Daniel Bastian","family":"Pfankuchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Philipp","family":"St\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Bendas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.07.013_bib0005","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 6","key":"10.1016\/j.bcp.2015.07.013_bib0010","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines","volume":"22","author":"Mandal\u00e0","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0015","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0025","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0037-1615937","article-title":"Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread","volume":"82","author":"Hettiarachchi","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2015.07.013_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-9966-27-21","article-title":"Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review","volume":"27","author":"Akl","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0035","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.23814","article-title":"Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review","volume":"113","author":"Akl","year":"2008","journal-title":"Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2015.07.013_bib0040","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0049-3848(14)50023-0","article-title":"Heparins and cancer survival: where do we stand?","volume":"133","author":"Noble","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.12381","article-title":"Coagulation and metastasis: what does the experimental literature tell us?","volume":"162","author":"Gil-Bernab\u00e9","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0050","doi-asserted-by":"crossref","first-page":"676731","DOI":"10.1155\/2012\/676731","article-title":"Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins","volume":"2012","author":"Bendas","year":"2012","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0055","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2015.07.013_bib0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E","article-title":"Subcutaneous heparin treatment increases survival in small cell lung cancer. Petites cellules group","volume":"74","author":"Lebeau","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2015.07.013_bib0065","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2015.07.013_bib0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000328014","article-title":"Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center","volume":"57","author":"Lebeau","year":"2011","journal-title":"Chemotherapy"},{"key":"10.1016\/j.bcp.2015.07.013_bib0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jso.20728","article-title":"Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer","volume":"95","author":"Icli","year":"2007","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0080","first-page":"411","article-title":"Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin","volume":"31","author":"Phillips","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","article-title":"Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer","volume":"6","author":"Modok","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4161\/cbt.4.3.1503","article-title":"Inhibition of p-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy","volume":"4","author":"Angelini","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2015.07.013_bib0095","doi-asserted-by":"crossref","first-page":"e41035","DOI":"10.1371\/journal.pone.0041035","article-title":"Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation","volume":"7","author":"Niu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.07.013_bib0100","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2015.07.013_bib0105","first-page":"525","article-title":"How liposomal cisplatin overcomes chemoresistance in ovarian tumour cells","volume":"34","author":"St\u00f6lting","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0110","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.bcp.2013.01.028","article-title":"Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling","volume":"85","author":"Koch","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/CPXCES13EA03","article-title":"Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathway","volume":"52","author":"St\u00f6lting","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.07.013_bib0120","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/hmg\/ddq042","article-title":"Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm","volume":"19","author":"Royer-Pokora","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2015.07.013_bib0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/mol.104.001198","article-title":"The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells","volume":"66","author":"Holzer","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/mol.109.063172","article-title":"Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs","volume":"77","author":"Howell","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2012.07.010","article-title":"Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells","volume":"116","author":"Kalayda","year":"2012","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bcp.2015.07.013_bib0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijpharm.2009.12.061","article-title":"Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro","volume":"389","author":"Krieger","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2015.07.013_bib0145","first-page":"5853","article-title":"Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients","volume":"9","author":"Samimi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0150","first-page":"1312","article-title":"Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance","volume":"60","author":"Komatsu","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2407-8-175","article-title":"Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells","volume":"8","author":"Kalayda","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2015.07.013_bib0160","doi-asserted-by":"crossref","first-page":"a004952","DOI":"10.1101\/cshperspect.a004952","article-title":"Heparan sulfate proteoglycans","volume":"3","author":"Sarrazin","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0165","first-page":"414","article-title":"Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues","volume":"47","author":"Behrens","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2015.07.013_bib0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tibs.2014.03.001","article-title":"Heparan sulfate signaling in cancer","volume":"39","author":"Knelson","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2015.07.013_bib0175","doi-asserted-by":"crossref","first-page":"0010","DOI":"10.1038\/msb4100014","article-title":"A comprehensive pathway map of epidermal growth factor receptor signaling","volume":"1","author":"Oda","year":"2005","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0180","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1242\/jcs.00786","article-title":"Novel functions and signalling pathways for GDNF","volume":"116","author":"Sariola","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2015.07.013_bib0185","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1096\/fj.07-8450com","article-title":"P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins","volume":"21","author":"Hostettler","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2015.07.013_bib0190","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/febs.12168","article-title":"The heparanase\/syndecan-1 axis in cancer: mechanisms and therapies","volume":"280","author":"Ramani","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2015.07.013_bib0195","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1074\/jbc.M112.439299","article-title":"The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology","volume":"288","author":"Harris","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.07.013_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.1997.3","article-title":"Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells","volume":"75","author":"Jayson","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2015.07.013_bib0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157016309789869001","article-title":"Therapeutic use of heparin beyond anticoagulation","volume":"6","author":"Ludwig","year":"2009","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0210","doi-asserted-by":"crossref","first-page":"26616","DOI":"10.1074\/jbc.M111.224212","article-title":"Heparin impairs angiogenesis through inhibition of microRNA-10b","volume":"286","author":"Shen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.07.013_bib0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2013-02-485011","article-title":"Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response","volume":"123","author":"Battinelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.07.013_bib0220","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1042\/bj2880953","article-title":"Heparin increases chromatin accessibility by binding the trypsin-sensitive basic residues in histones","volume":"288","author":"Villeponteau","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2015.07.013_bib0225","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.30211","article-title":"Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes","volume":"63","author":"Hedberg","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2015.07.013_bib0230","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/febs.12111","article-title":"Syndecan-1 modulates \u03b2-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation","volume":"280","author":"Hassan","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2015.07.013_bib0235","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jcp.2010.080234","article-title":"Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary","volume":"63","author":"Umezu","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcp.2015.07.013_bib0240","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1242\/jcs.140871","article-title":"Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling","volume":"127","author":"Capurro","year":"2014","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2015.07.013_bib0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1242\/jcs.091876","article-title":"Localization of glypican-4 in different membrane microdomains is involved in the regulation of Wnt signaling","volume":"125","author":"Sakane","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2015.07.013_bib0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/dna.2014.2626","article-title":"Interference with the expression of \u03b2-catenin reverses cisplatin resistance in A2780\/DDP cells and inhibits the progression of ovarian cancer in mouse model","volume":"34","author":"Zhao","year":"2015","journal-title":"DNA Cell Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215003834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215003834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T15:29:49Z","timestamp":1599406189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215003834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0006295215003834"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.013","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}